The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer.

Zhiyao FanKun FanYitao GongQiuyi HuangChao YangHe ChengKaizhou JinQuanxing NiXian-Jun YuGuopei LuoChen Liu

Published in: Cancer management and research (2019)

CRP/Alb is a strong and useful indicator of prognosis for advanced pancreatic cancer. Both baseline and postchemotherapy CRP/Alb can be used in predicting the survival of patients and monitoring the effectiveness of chemotherapy in clinical practice.

Keyphrases

randomized controlled trial
clinical practice
end stage renal disease
systematic review
ejection fraction
chronic kidney disease
prognostic factors
free survival
radiation therapy
patient reported